to me the risk near term is immunogenicity, and the decline in leukocytes that no one is talking about
Don't say no one. I've posted multiple times that immunogenicity is something I'm curious about.
I'm also a little surprised that the abstract notes some duration of stable disease but no explicit mention of any objective responses. There were none at this point, or are the data simply being kept under wraps for now?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.